There are 3158 resources available
CN86 - Review of nursing interventions for the management of psychosocial problems in adults after hematopoietic stem cell transplantation: A systematic review
Presenter: Aysenur Cetin Uceriz
Session: Rehabilitation and survivorship care
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA63 and 1504MO
Presenter: Arndt Vogel
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO-SIOG: Working together in the era of personalized care for older adults with cancer
Resources:
Webcast
1962O - Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma
Presenter: Jens Bedke
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
Slides
Webcast
73MO - Longitudinal probing of combinatorial immunotherapy (anti-VEGF/anti-PD1) response in advanced nasopharyngeal carcinoma, at single cell resolution
Presenter: Shu-Mei Chia
Session: Mini oral session: Basic science & Translational research
Resources:
Abstract
Webcast
965MO - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW
Presenter: Thomas Decaens
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
350MO - Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – Second interim efficacy analysis of the randomized phase III DETECT V trial
Presenter: Wolfgang Janni
Session: Mini oral session 2: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Rehabilitation and survivorship care
Resources:
Webcast
MDT: Prostate cancer - Case of an older adult with metastatic prostate cancer
Session: ESMO-SIOG: Working together in the era of personalized care for older adults with cancer
Resources:
Webcast
947MO - Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Lorenza Rimassa
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast